Bispecific antibody toxicities
Unlike monoclonal antibodies, bispecific antibodies bind to 2 different antigens simultaneously,[1][1] directing T cells toward cancer cells to exert a cytotoxic killing effect.[1][1] Bispecific antibodies are used as monotherapy treatment of relapsed or treatment-refractory malignancies, including
Authors
- Joanne Britto
- Amaris Balitsky (ORCID: https://orcid.org/0000-0002-2831-9107)
- Gwynivere A Davies (ORCID: https://orcid.org/0000-0003-4472-6535)
- Hira S. Mian (ORCID: https://orcid.org/0000-0003-1584-1067)
Institutions
- Juravinski Cancer Centre (CA)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1503/cmaj.241384
- Citations
- 2
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.72